Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Mergers & Acquisitions
Pharmaceutical company announces provisional results of offer to buy Aventis
September 8th, 2004
Sanofi-Synthelabo (SNY) announced that the French Autorite des marches financiers (AMF) published the provisional results of its offers for Aventis. Aventis Pharmaceuticals is the U.S. pharmaceuticals business of Aventis, an international pharmaceuticals and human vaccines company. These results indicate that, as of the expiration of the offers, in aggregate 769,920,773 Aventis shares had been tendered into the French, German and U.S. offers, including the Aventis shares underlying ADSs tendered into the U.S. offer. In addition, 92,692 warrants issued by Aventis in 2002 and 164,556 warrants issued by Aventis in 2003 were tendered into the French...
Source: Vaccine Weekly (2004-09-08)
|
